Comparing 32 approaches for cancer
Official title: Pan Tumor Rollover Study
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
- Phase 2
- 32 groups
- Sites in Edmonton, Vancouver and 4 more cities
- Recruiting
Interventions (19)
- Medication
Nivolumab
Specified dose on specified days
- Medication
Ipilimumab
Specified dose on specified days
- Medication
Cabozantinib
Specified dose on specified days
- Medication
Trametinib
Specified dose on specified days
- Medication
Relatlimab
Specified dose on specified days
- Medication
Nivolumab + Relatlimab
Specified dose on specified days
- Medication
Capecitabine
Specified dose on specified days
- Medication
Bevacizumab
Specified dose on specified days
- Medication
Temozolomide
Specified dose on specified days
- Medication
Rucaparib
Specified dose on specified days
- Medication
Daratumumab
Specified dose on specified days
- Medication
Regorafinib
Specified dose on specified days
- Medication
Leucovorin
Specified dose on specified days
- Medication
Fluorouracil
Specified dose on specified days
- Medication
Oxaliplatin
Specified dose on specified days
- Medication
Enzalutamide
Specified dose on specified days
- Medication
Sunitinib
Specified dose on specified days
- Medication
Pemetrexed
Specified dose on specified days
- Medication
Pembrolizumab
Specified dose on specified days
Canadian Sites (7)
2 of 7 recruiting
- Recruiting
Cross Cancer Institute
Edmonton, Alberta
- Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario
- Withdrawn
Local Institution
Vancouver, British Columbia
- Withdrawn
Local Institution
Halifax, Nova Scotia
- Completed
Local Institution - 0168
Oshawa, Ontario
- Withdrawn
Local Institution - 0040
Montreal, Quebec
- Withdrawn
Local Institution - 0308
Montreal, Quebec
Eligibility Criteria
See who this study is looking for13 criteria
The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.
Inclusion
- +Signed Written Informed ConsentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →.
- +Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → assessment in the Parent Study.
- +On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study.
- +Exclusion CriteriaExclusion criteriaThe things that would prevent someone from taking part.Read more →
- +Participant is not eligible for study treatment per the Parent Study eligibility criteriaEligibility criteriaThe full list of requirements for taking part in a study.Read more →.
- +Participants not receiving clinical benefit as assessed by the Investigator.
- +Any clinical adverse eventAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
- +Other protocolProtocolThe detailed plan a study must follow.Read more →-defined InclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more →/Exclusion Criteria apply
- +WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF.
Exclusion
- −Participant is not eligible for study treatment per the Parent Study eligibility criteriaEligibility criteriaThe full list of requirements for taking part in a study.Read more →.
- −Participants not receiving clinical benefit as assessed by the InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →.
- −Any clinical adverse eventAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant.
- −Other protocolProtocolThe detailed plan a study must follow.Read more →-defined InclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more →/Exclusion CriteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → apply
In plain language
Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.
What this study is
This study is testing a treatment for a condition.
Phase 2Phase 2A middle-stage study looking at what a treatment does and watching for side effects.Read more → — a middle-stage study in a few hundred people at most, looking at what the treatment does and watching for side effectsSide effectAn unwanted effect thought to be caused by the treatment itself.Read more →.
From the trial registry
Built from these fields:
- designModule.designInfo.primaryPurpose
- designModule.phases
Who receives what
There are 32 groups in this study.
Groups A, B and U receive Nivolumab.
Registry label: A: A1: Nivolumab Monotherapy Dose 1 · B: A2: Nivolumab Monotherapy Dose 2 · U: D4: Nivolumab + Bevacizumab
Groups C and J receive Nivolumab and Ipilimumab.
Registry label: C: B1: Nivolumab + Ipilimumab · J: C5: Relatlimab + Nivolumab + Ipilimumab
Group D receives Nivolumab, Ipilimumab and Cabozantinib.
Registry label: D: B2: Nivolumab + Ipilimumab + Cabozantinib
Group E receives Nivolumab, Ipilimumab and Trametinib.
Registry label: E: B3: Nivolumab + Ipilimumab + Trametinib
Groups F and G receive Nivolumab + Relatlimab.
Registry label: F: C1: Relatlimab + Nivolumab Fixed Dose Combination Dose 1 · G: C3: Relatlimab + Nivolumab Fixed Dose Combination Dose 2
Groups H, I, L, M, N, O and Q receive Relatlimab and Nivolumab.
Registry label: H: C2: Relatlimab + Nivolumab Single Agent Vial (SAV) Dose 1 · I: C4: Relatlimab + Nivolumab SAV Dose 2 · L: C7: Relatlimab + Nivolumab SAV Dose 3 · M: C10: Relatlimab + Nivolumab SAV Dose 4 · N: C12: Relatlimab + Nivolumab SAV Dose 5 · O: C8: Relatlimab + Nivolumab SAV + PDCT Dose 1 · Q: C11: Relatlimab + Nivolumab SAV + PDCT Dose 2
Group K receives Capecitabine, together with one or more of: Nivolumab + Relatlimab.
Registry label: K: C6: Relatlimab + Nivolumab + Capecitabine
Group P receives Relatlimab, Nivolumab and Bevacizumab.
Registry label: P: C9: Relatlimab + Nivolumab SAV + Bevacizumab
Group R receives Nivolumab and Temozolomide.
Registry label: R: D1: Nivolumab + Temozolomide
Group S receives Nivolumab and Rucaparib.
Registry label: S: D2: Nivolumab + Rucaparib
Group T receives Nivolumab and Daratumumab.
Registry label: T: D3: Nivolumab + Daratumumab
Group V receives Bevacizumab.
Registry label: V: E1: Bevacizumab Monotherapy
Group W receives Regorafinib.
Registry label: W: E2: Regorafinib Monotherapy
Group X receives Leucovorin, Oxaliplatin and Fluorouracil.
Registry label: X: E4: Leucovorin + Oxaliplatin + Fluorouracil
Group Y receives Enzalutamide.
Registry label: Y: E5: Enzalutamide Monotherapy
Group Z receives Sunitinib.
Registry label: Z: E6: Sunitinib Monotherapy
Group AA receives Rucaparib.
Registry label: AA: E7: Rucaparib Monotherapy
Group AB receives Capecitabine.
Registry label: AB: E8: Capecitabine Monotherapy
Group AC receives Cabozantinib.
Registry label: AC: E9: Cabozantinib Monotherapy
Group AD receives Pemetrexed.
Registry label: AD: E10: Pemetrexed Monotherapy
Group AEAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → receives Pembrolizumab.
Registry label: AE: E11: Pembrolizumab Monotherapy
Group AF receives Leucovorin.
Registry label: AF: E3: Leucovorin + Fluorouracil
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].label
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
How the study is run
Groups are assigned by the study team using set rules, rather than by chance.
This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.
From the trial registry
Built from these fields:
- designModule.designInfo.allocation
- designModule.designInfo.maskingInfo.masking
Is there a placebo?
This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for
The study lists a minimum age of 18 years, with no upper limit given.
The study is open to people of any sex.
The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.
From the trial registry
Built from these fields:
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How big and how long
The study aims to enrol about 1,500 people.
The study is currently expected to finish around August 2029.
The main measurement is taken over: From Day 1 up to 135 Days after discontinuation of treatment.
From the trial registry
Built from these fields:
- designModule.enrollmentInfo.count
- statusModule.completionDateStruct.date
- outcomesModule.primaryOutcomes[].timeFrame
What the study measures
Incidence of Adverse EventsAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more → (AEs) — measured over From Day 1 up to 135 Days after discontinuation of treatment.
Incidence of drug related AEs — measured over From Day 1 up to 135 Days after discontinuation of treatment.
Incidence of AEs leading to Discontinuation — measured over From Day 1 up to 135 Days after discontinuation of treatment.
Incidence of Serious Adverse EventsSerious adverse eventAn adverse event meeting a formal severity threshold, such as requiring hospital admission.Read more → (SAEs) — measured over From signature of Informed ConsentInformed consentThe process of being told what taking part involves, then choosing freely.Read more → up to 135 Days after discontinuation of treatment.
The study lists 3 further main measurements.
From the trial registry
Built from these fields:
- outcomesModule.primaryOutcomes[].measure
- outcomesModule.primaryOutcomes[].timeFrame
Source: NCT03899155 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.
Not medical advice. What do these terms mean?
What is being tested — in plain terms
About NivolumabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About IpilimumabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About CabozantinibDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About TrametinibDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About RelatlimabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About Nivolumab + RelatlimabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About CapecitabineDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About BevacizumabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About TemozolomideDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About RucaparibDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About DaratumumabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About RegorafinibDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About LeucovorinDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About FluorouracilDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About OxaliplatinDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About EnzalutamideDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About SunitinibDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About PemetrexedDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About PembrolizumabDrug
Specified dose on specified days
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
Common questions
Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.
Am I eligible for this trial?
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.
What the study lists: a minimum age of 18 years.
The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.
The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.eligibilityCriteria
Is there a placebo?
This study does not list a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → group.
From the trial registry
- armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?
This study is open-labelOpen-labelEveryone knows which treatment is being given — nothing is hidden.Read more →: everyone knows which treatment is being given, including you and the study team.
Groups are assigned by the study team using set rules, rather than by chance.
From the trial registry
- designModule.designInfo.maskingInfo.masking
- designModule.designInfo.allocation
Who can join?
The study lists a minimum age of 18 years, with no upper limit given.
It is open to people of any sex.
It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How long would this take?
The study's main measurement is taken over: From Day 1 up to 135 Days after discontinuation of treatment.
The study as a whole is currently expected to finish around 2029-08-25.
How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.
From the trial registry
- outcomesModule.primaryOutcomes[].timeFrame
- statusModule.completionDateStruct.date
How many people are taking part?
The study aims to enrol about 1,500 people.
From the trial registry
- designModule.enrollmentInfo.count
Where is this happening?
This study lists 12 locations, including: Edmonton, Alberta, Canada; Vancouver, British Columbia, Canada; Halifax, Nova Scotia, Canada; Oshawa, Ontario, Canada; Toronto, Ontario, Canada; Montreal, Quebec, Canada, and 6 more.
Sites can open and close during a study, so confirm with the team before travelling.
From the trial registry
- trial_locations
About This Trial
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Other Sites (9)
Local Institution - 0143
Ann Arbor, Michigan, United States
Local Institution - 0100
Minneapolis, Minnesota, United States
Local Institution - 0128
Buffalo, New York, United States
NYU Langone Hematology Oncology Associates-Mineola
Mineola, New York, United States
Local Institution
New York, New York, United States
Local Institution - 0185
New York, New York, United States
Local Institution - 0202
New York, New York, United States
Local Institution
New York, New York, United States
Public Hospital of King County District 1 Valley Medical Center
Renton, Washington, United States
Think this trial might be right for you?
Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.
See if this trial could fit youThis page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.